
    
      Patients wiith selected malignant or non-malignant conditions meeting eligibility criteria
      will be enrolled on this study. Patients will receive one of either full intensity, reduced
      intensity, or reduced toxicity conditioning appropriate based on disease, disease status,
      organ function and performance status and will undergo α/β T-cell and CD 19+ B cell depleted
      alloSCT.

      Patients will be following for engraftment, chimerism, immune reconstitution, GVHD and QOL.
    
  